Should Investors Brace for Bad News From Novavax's Looming Clinical Update?
One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a clinical study. All Novavax did was announce that a call would be held on Monday, July 24, to discuss results from a phase 2 study of its RSV F vaccine.
Based on the stock's surge, investors were obviously viewing the update as a positive development. Despite no mention whatsoever in Novavax's press release about how well its RSV F vaccine performed, many automatically assumed good news. But should investors brace themselves for bad news instead?
Image source: Getty Images.
Source: Fool.com
Novavax Inc. Stock
€3.91
2.600%
Based on 3 Buy predictions and 2 Sell predictions the sentiment towards Novavax Inc. is rather balanced.
With a target price of 12 € there is potential for a 207.1% increase which would mean more than doubling the current price of 3.91 € for Novavax Inc..
